Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischemic stroke. Results of a phase IIa randomized trial.

@article{Grotta1995SafetyAT,
  title={Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischemic stroke. Results of a phase IIa randomized trial.},
  author={James C. Grotta and Wayne Clark and Bruce M. Coull and Luther Creed Pettigrew and Bruce Mackay and Larry B. Goldstein and Irene Meissner and Declan Murphy and L Larue},
  journal={Stroke},
  year={1995},
  volume={26 4},
  pages={602-5}
}
BACKGROUND AND PURPOSE CGS 19755 is a competitive N-methyl-D-aspartate (NMDA) receptor antagonist that limits neuronal damage in animal stroke models. The objectives of this multicenter (7 centers), randomized, double-blind, placebo-controlled, ascending-dose phase IIa study were to evaluate the safety and tolerability of CGS 19755 and obtain pharmacokinetic and preliminary data on its efficacious dose range in patients treated within 12 hours of hemispheric ischemic stroke. METHODS At each… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 54 extracted citations

Similar Papers

Loading similar papers…